Valion BioVBIO
13F holders, Q4 2025 (December 31)7holders
2new positions
1sold out
$1.45avg. 13F price*
At the end of Q4 2025, 7 institutions reported holding Valion Bio Inc. (VBIO) in their 13F filings, unchanged from Q3 2025. 2 opened new positions and 1 sold out. The largest holders were Marex Group Ltd ($59K), UBS Group AG ($29K) and Susquehanna International Group, LLP ($21K).
- Company
- Valion Bio Inc.
- Filed as
- TIVIC HEALTH SYSTEMS INC (Q4 2025)
- CUSIP
- 888705308
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $24K |
| Exits | 1 | $156K |
All 13F filers, Q3 2025 → Q4 2025: 41,267 shares bought and 53,935 shares sold, net −12,668 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Marex Group Ltd | 0.00% | Add +6.6% | 40,942 | $59K |
| UBS Group AG | 0.00% | Add +2354.3% | 19,659 | $29K |
| Susquehanna International Group, LLP | 0.00% | New | 14,639 | $21K |
| Citigroup Inc. | 0.00% | Add +249.5% | 4,998 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 1,648 | $2K |
| SBI Securities Co., Ltd. | 0.00% | No change | 16 | $23 |
| Bank of America Corp. | 0.00% | Add +62.5% | 13 | $19 |
"% of holder's portfolio" is VBIO's weight in each manager's 13F, not the share of Valion Bio Inc. the manager owns.